<i id='6AE055DA8E'><strike id='6AE055DA8E'><tt id='6AE055DA8E'><pre id='6AE055DA8E'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Hollywood unions extend contract negotiations for actors 
'Reaching a detente': STAT's Helen Branswell on covering Covid 
Affirmative action in medical school literally saved lives 
Stanford president to resign after investigation of research 
Cancer drug shortages should be causing more outrage 
Pfizer's Covid pill remains 89% effective in final analysis, company says 
Supreme Court strikes down use of affirmative action 
Duchenne patients, backed by ‘dark money’ group, to debate drug prices
Affirmative action in medical school literally saved lives 
Can food be medicine? And other questions about a new push 
State Dept. review finds Biden bears some blame for Afghanistan failures 
4th of July breaks record for highest global temperature ever measured 
BioMarin wins approval for gene therapy to treat hemophilia A 
When is a doctor not a doctor? Try when patients address women doctors 
The cancer drug shortage isn’t new — and neither are the solutions 
